

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address Commissioner of PATENTS AND TRADEMARKS Washington DC 20231 www.uspto.gov

APPLICATION NO.	HLING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/068,528	05/13/1998	SATOSHI KOIZUMI	766.20	2408		
5514 FITZPATR	5514 7590 04/18/2002 FITZPATRICK CELLA HARPER & SCINTO			EXAMINER		
30 ROCKEFELLER PLAZA NEW YORK, NY 10112			RAO, MANJUNATH N			
	,		ART UNIT	PAPER NUMBER		
			1652			

DATE MAILED: 04/18/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.		Applicant(s)			
	-	09/068,528		KOIZUMI ET AL.			
	Office Action Summary	Examiner		Art Unit			
		Manjunath N Rao		1652			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address							
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM							
THE M - Extens after S - If the p - If NO   - Failure - Any re earned	AAILING DATE OF THIS COMMUNICATION.  sions of time may be available under the provisions of 37 CFR 1.1.  siX (6) MONTHS from the mailing date of this communication.  beriod for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period of the to reply within the set or extended period for reply will, by statute the ply received by the Office later than three months after the mailing displayment. See 37 CFR 1.704(b).	36(a). In no event, howevery within the statutory minim will apply and will expire SIX	r, may a reply be tin um of thirty (30) day ( (6) MONTHS from ecome ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status	The second properties (c) filed on 04 h	Eehruary 2002					
1)⊡	OLIVE This action is non-final						
2a)□	11110 4041011 10 1 11 11 1			rosecution as to the merits is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
	on of Claims						
	Claim(s) 1,5,8 and 15-20 is/are pending in the		ion				
	4a) Of the above claim(s) is/are withdrawn from consideration.						
-	5) Claim(s) is/are allowed.						
	6) Claim(s) <u>1,5,8 and 15-20</u> is/are rejected.						
	Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.  Application Papers							
• •	The specification is objected to by the Examine	er.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11)	The proposed drawing correction filed on	_ is: a)∏ approved	d b)⊡ disappr	roved by the Examiner.			
•	If approved, corrected drawings are required in re						
12) The oath or declaration is objected to by the Examiner.							
	under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
	a)  The translation of the foreign language p Acknowledgment is made of a claim for dome	rovisional application	on has been re	eceived.			
Attachme							
2) Noti	ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449) Paper No(s)	4)		ary (PTO-413) Paper No(s) al Patent Application (PTO-152)			

Art Unit: 1652

### **DETAILED ACTION**

Claims 1, 5, 8, 15-20 are still at issue and are present for examination.

Applicants' arguments filed on 2-4-02, paper No. 31, have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 5, 8, 15-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Akihiko et al. (EP 0553821A1, 4-8-93), Zapata et al. (J. Biol. Chem. Vol. 264(25):14769-14774) and the common knowledge in the art that CMP-NeuAc can be synthesized from CTP and NeuAc (Biochemistry, 3<sup>rd</sup> Ed, 1988, by Stryer). Claims 1, 5, 8, 15-20 are drawn to a method of synthesizing a sugar –nucleotide such as CMP-sialic acid by combining a) culture broth, supernatant etc. of a microorganism (such as *C.ammoniagenes*) capable of producing NTP from a nucleotide precursor; b)a culture broth, culture supernatant etc. of a microorganism (such as *E.coli* or *C.ammoniagenes*) having genes responsible for production of sugar-nucleotide from a sugar selected from a group consisting of glucose, fructose, galactose, sialic acid etc., allowing the enzyme sources the nucleotide precursor and the sugar to be present in an aqueous medium to form and accumulate the sugar-nucleotide and recover the same.

Art Unit: 1652

Akihiko et al. teach the synthesis of CTP-choline using orotic acid from two groups of microorganisms which they call as Microorganism A2 and microorganism B. While microorganism B (*C.ammoniagenes*) has the capability of converting orotic acid to UTP, microorganism A2 (*E.coli*)has the capability of converting UTP to CTP and CTP-choline only in the presence of phosphorylcholine. However, it would be obvious to one of skill in the art that microorganism A2 will accumulate the CTP when phosphorylcholine is deleted from the reaction.

Zapata et al. teach the cloning of gene which is responsible for encoding sialic acid synthase which forms CMP-sialic acid in the presence of CTP and sialic acid. The reference provides a clone which expresses the gene by 10-30 folds in excess of what is produced by the wild type.

Therefore, it would have been obvious to one of ordinary skill in the art, especially those interested in developing a simple and cost-effective method of preparing CMP-sialic acid, by growing the Microorganism A2 and microorganism B of Akihiko et al. (which produces CTP starting from orotic acid) along with the clone of Zapata et al. in a medium comprising orotic acid and sialic acid to produce CMP-sialic acid. One of ordinary skill in the art would have been motivated to do as other methods to produce the same sugar-nucleotide is either cumbersome or not cost-effective. One of ordinary skill in the art would have a reasonable expectation of success since the reference of Akihiko et al. explicitly teach and provide the required microorganisms to produce CTP from a cheap substrate such as orotic acid and Zapata et al. provide a clone that can form CMP-sialic acid from sialic acid and CTP. Therefore, the above invention would have been *prima facie* obvious to one of ordinary skill in the art.

Art Unit: 1652

#### **Double Patenting**

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1, 5, 8, 15-20 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 72-80 of copending Application No. 09/907,574. Although the conflicting claims are not identical, they are not patentably distinct from each other because the claims are drawn to the same subject matter of a process for producing a sugar nucleotide comprising selecting as enzyme sources a culture broth of a microorganism capable of producing nucleoside-5"-triphosphate (NTP) from a nucleotide precursor, or a treated product of culture broth and b) a culture broth or culture broths of at least one strain of microorganism having gnenes responsible for production of a sugar nucleotide from a sugar and NTP or a treated product of the culture broth, allowing the enzyme sources, the nucleotide precursor and the sugar to be present in an aqueous medium to form and accumulate the sugar nucleotide in the aqueous medium and recovering the sugar nucleotide from the aqueous medium.

Art Unit: 1652

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

#### Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Steadman whose telephone number is (703) 308-3934. The Examiner can normally be reached on M-F from 7:30 a.m. to 4:00 p.m. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, P.Achutamurthy, can be reached on (703) 308-3804. The fax number for Official Papers to Technology Center 1600 is (703) 305-3014. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

REBECCA E. PROUTY PRIMARY EXAMINER GROUP-1800

David Steadman. Ph.D. April 9, 2002